Blog

• Earlier this week, Zimmer Biomet Holdings showcased its latest orthopedic robotics and digital health innovations, including FDA-cleared mBos TKA System and the recently acquired Monogram Technologies robotic platform, at the annual meeting of the American Association of Hip and Knee Surgeons.

• A standout revelation was the integration of AI-driven and autonomous technologies into the company’s expanding knee and hip portfolios, reflecting Zimmer Biomet’s commitment to advancing surgical precision and connected care solutions.

• We’ll examine how Zimmer Biomet’s integration of AI-driven orthopedic robotics could reshape the long-term outlook for its investment narrative.

Trump has pledged to “unleash” American oil and gas and these 22 US stocks have developments that are poised to benefit.

To be a shareholder in Zimmer Biomet, you need to believe in the power of innovation in orthopedic robotics and digital health to drive demand for advanced surgical solutions. This week’s showcase of FDA-cleared and AI-powered products could energize sentiment but is unlikely to meaningfully shift the company’s near-term reliance on successful product launches; ongoing industry pricing pressures still remain the key headwind.

Among the latest announcements, the FDA clearance of the mBos TKA System stands out for its relevance, as it highlights Zimmer Biomet’s efforts to keep pace in the competitive race for autonomous robotics and supports the company’s narrative of product-driven growth, even as full regulatory approvals for other key technologies remain pending.

In contrast, investors should be aware of increasing pricing pressures and the consequences if these persist through…

Read the full narrative on Zimmer Biomet Holdings (it’s free!)

Zimmer Biomet Holdings is projected to reach $9.2 billion in revenue and $1.3 billion in earnings by 2028. This outlook assumes a 5.5% annual revenue growth rate and an earnings increase of about $476 million from the current $823.5 million.

Uncover how Zimmer Biomet Holdings’ forecasts yield a $110.92 fair value, a 8% upside to its current price.

Simply Wall St Community members estimate fair value for Zimmer Biomet anywhere between US$95 and US$167.48 per share, with three unique perspectives. As these opinions range widely, consider the risk of ongoing pricing pressures that could challenge margin recovery and ultimately affect future earnings.

Explore 3 other fair value estimates on Zimmer Biomet Holdings – why the stock might be worth 8% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ZBH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com